Hypothyroidism Is a Predictive Factor for Better Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Undergoing Lenvatinib Therapy

SIMPLE SUMMARY: Patients with advanced hepatocellular carcinoma (HCC) undergoing molecular targeted therapy often experience non-negligible adverse events (AEs). Paradoxically, certain AEs are reportedly associated with a good prognosis. We aimed to identify factors predictive of treatment duration...

Descripción completa

Detalles Bibliográficos
Autores principales: Shomura, Masako, Okabe, Haruka, Sato, Emi, Fukai, Kota, Shiraishi, Koichi, Hirose, Shunji, Tsuruya, Kota, Arase, Yoshitaka, Anzai, Kazuya, Kagawa, Tatehiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7690372/
https://www.ncbi.nlm.nih.gov/pubmed/33105621
http://dx.doi.org/10.3390/cancers12113078

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7690372/
https://www.ncbi.nlm.nih.gov/pubmed/33105621
http://dx.doi.org/10.3390/cancers12113078

Ejemplares similares